Account
Inquiry
Tirzepatide, also known as LY3298176, is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. This compound is primarily used in research for type 2 diabetes treatment and weight management studies. It exhibits a higher affinity for GIP receptors compared to GLP-1 receptors, leading to enhanced efficacy in reducing hyperglycemia.
In clinical trials, Tirzepatide has demonstrated significant weight loss results. For instance, the SURMOUNT-1 trial reported average weight reductions of 15% at 5mg, 19.5% at 10mg, and 20.9% at 15mg doses over 72 weeks. These findings highlight its potential in obesity and related metabolic research.
The molecular structure of Tirzepatide includes a PEG-modified lysine side chain, which improves water solubility and stability. This modification supports its functionality as a research compound, ensuring consistent performance in experimental settings.
Proper storage is essential for maintaining Tirzepatide's integrity. Store in a cool, dry, and dark place, avoid repeated freezing and thawing, minimize air exposure, and protect from light. For long-term stability, aliquot according to experimental needs and avoid storing in solution.
This product is intended for research use only and not for human consumption. Researchers should follow all safety protocols and regulatory guidelines when handling Tirzepatide.
